Related references
Note: Only part of the references are listed.In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies
Roberta Rosa et al.
CURRENT MEDICINAL CHEMISTRY (2014)
Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells
Alex Y. Chang et al.
BMC CANCER (2013)
PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer
Amanda Herzog et al.
CLINICAL CANCER RESEARCH (2013)
The novel phosphoinositide 3-kinasemammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor
Takako Sano et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Has a Therapeutic Potential and Sensitizes Cisplatin in Nasopharyngeal Carcinoma
Fen Yang et al.
PLOS ONE (2013)
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
Vivian W. Y. Lui et al.
CANCER DISCOVERY (2013)
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
Toshio Shimizu et al.
CLINICAL CANCER RESEARCH (2012)
Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
Giorgia Migliardi et al.
CLINICAL CANCER RESEARCH (2012)
mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma
Hala Elnakat Thomas et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
Roberta Rosa et al.
CLINICAL CANCER RESEARCH (2011)
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
Robert Mallon et al.
CLINICAL CANCER RESEARCH (2011)
Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
D. A. Sabbah et al.
CURRENT MEDICINAL CHEMISTRY (2011)
EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy
Christian Freudlsperger et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
Efficient Blockade of Akt signaling is a determinant factor to overcome resistance to Matuzumab
Debora D. Meira et al.
MOLECULAR CANCER (2011)
MOLECULAR AND CLINICAL RESPONSES IN A PILOT STUDY OF GEFITINIB WITH PACLITAXEL AND RADIATION IN LOCALLY ADVANCED HEAD-AND-NECK CANCER
Carter Van Waes et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Effect of cetuximab treatment in squamous cell carcinomas
Marika Nestor
TUMOR BIOLOGY (2010)
Proteomic Signatures of Epidermal Growth Factor Receptor and Survival Signal Pathways Correspond to Gefitinib Sensitivity in Head and Neck Cancer
Francisco G. Pernas et al.
CLINICAL CANCER RESEARCH (2009)
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
Ta-Jen Liu et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3
Meghan B. Azad et al.
AUTOPHAGY (2008)
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
R. Bianco et al.
BRITISH JOURNAL OF CANCER (2008)
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells
Roberto Bianco et al.
CLINICAL CANCER RESEARCH (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
Autophagy in Niemann-Pick C disease is dependent upon Beclin-1 and responsive to lipid trafficking defects
Chris D. Pacheco et al.
HUMAN MOLECULAR GENETICS (2007)
Distinct roles of autophagy in the heart during ischemia and reperfusion - Roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy
Yutaka Matsui et al.
CIRCULATION RESEARCH (2007)
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy
A. Jimeno et al.
BRITISH JOURNAL OF CANCER (2007)
Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer
Cherie-Ann O. Nathan et al.
CANCER RESEARCH (2007)
Dissecting the Akt/Mammalian target of rapamycin signaling network: Emerging results from the head and neck cancer tissue array initiative
Alfredo A. Molinolo et al.
CLINICAL CANCER RESEARCH (2007)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Reuben J. Shaw et al.
NATURE (2006)
Growing roles for the mTOR pathway
DD Sarbassov et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
Monoclonal antibodies targeting the epidermal growth factor receptor
R Bianco et al.
CURRENT DRUG TARGETS (2005)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni et al.
LANCET ONCOLOGY (2005)
Frequent genetic and biochemical alterations of the PI3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma
JMG Pedrero et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01
P Amornphimoltham et al.
CLINICAL CANCER RESEARCH (2004)
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines
CC Bancroft et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
A novel conditional Akt 'survival switch' reversibly protects cells from apoptosis
B Li et al.
GENE THERAPY (2002)
Share Paper
